Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...